Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q06265
UPID:
EXOS9_HUMAN
Alternative names:
Autoantigen PM/Scl 1; Exosome component 9; P75 polymyositis-scleroderma overlap syndrome-associated autoantigen; Polymyositis/scleroderma autoantigen 1; Polymyositis/scleroderma autoantigen 75 kDa
Alternative UPACC:
Q06265; Q12883; Q4W5P5; Q86Y41; Q86Y48
Background:
Exosome complex component RRP45, also known as Exosome component 9, plays a crucial role in RNA processing and degradation. It is a non-catalytic component of the RNA exosome complex, involved in the maturation of stable RNA species and the elimination of RNA processing by-products. Its activities span both nuclear and cytoplasmic realms, facilitating the degradation of unstable mRNAs and participating in RNA surveillance pathways.
Therapeutic significance:
The protein's involvement in Pontocerebellar hypoplasia 1D, a severe neurologic disorder, underscores its therapeutic significance. Understanding the role of Exosome complex component RRP45 could open doors to potential therapeutic strategies for this and related disorders.